Volume 5 Number 1 2026
Immunomodulatory Nanovaccines with Built-In Imaging Tags for Tracking Lymph Node Delivery In Vivo
Bassam Mohammad A. Abualsoud 1*
Biosensors and Nanotheranostics 5 (1) 1-8 https://doi.org/10.25163/biosensors.5110991
Submitted: 11 April 2026 Revised: 01 June 2026 Accepted: 08 June 2026 Published: 10 June 2026
Cancer nanovaccines promise durable, tumor-specific immunity, yet most candidates are still evaluated as though delivery were a solved problem. It is not. Whether an injected formulation actually reaches the tumor-draining lymph node, and what it does once there, has historically been inferred from end-point tissue harvests rather than observed directly. This review examines a convergent solution: immunomodulatory nanovaccines carrying built-in imaging tags that report, in real time and in vivo, where the vaccine goes and how the immune system responds. We first consolidate the physicochemical rules that govern lymphatic trafficking, where particle size (most efficiently 20–50 nm), surface charge, geometry, elasticity, and ligand decoration jointly determine interstitial transit, nodal retention, and uptake by antigen-presenting cells. We then survey antigen–adjuvant co-delivery architectures, from whole-tumor-cell and biomimetic-membrane platforms to carrier-free and dual TLR/STING systems, that drive dendritic-cell maturation and MHC-I cross-presentation. The core of the review compares the imaging modalities themselves, optical (NIR-I/NIR-II), nuclear (PET/SPECT), magnetic (MRI/MPI), and genetic reporters, each trading penetration against resolution. Finally, we connect tracking metrics to immunological outcomes: cytotoxic T-cell priming, tumor-microenvironment reprogramming, checkpoint synergy, and tertiary lymphoid structure neogenesis. Persistent barriers, tracer dissociation, reticuloendothelial clearance, and manufacturing reproducibility, are discussed as the gating problems for clinical translation.
Keywords: cancer nanovaccine; lymph node targeting; theranostics; in vivo imaging; dendritic cells; cross-presentation; tertiary lymphoid structures; immune checkpoint blockade
Bao, C. J., Zhang, X. Y., Wang, Y. L., Liu, Y., & Chen, Z. (2026). PLGA-based nanovaccines promote lymph node drainage and dendritic cell cross-presentation for enhanced cancer immunotherapy. Carbohydrate Polymers, 373, 124618.
Farooq, M. A., Trevaskis, N. L., & Porter, C. J. H. (2025). Design and assessment of nano delivery systems for lymph node delivery and cancer immunotherapy. Acta Biomaterialia, 193, 65–82.
Golshan, A., Hawii, G., & Aniya, C. (2017). Principles guiding the rational design of particles for vaccine delivery. ACS Nano, 11(1), 54–68.
Guo, J., Liu, C., Qi, Z., Qiu, T., Zhang, J., & Yang, H. (2024). Engineering customized nanovaccines for enhanced cancer immunotherapy. Bioactive Materials, 36, 330–357.
Huang, C., Wang, H., Luo, S., Yu, C., Zhang, L., & Zhu, D. (2026). Advances in delivery technologies-powered cancer vaccines. Bioactive Materials, 61, 498–533.
Jewell, C. M., López, S. C. B., & Irvine, D. J. (2011). In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proceedings of the National Academy of Sciences, 108(38), 15745–15750.
Jin, C., Ye, T., & Wang, J. (2024). Mannose-modified lipid-based nanovaccines for specifically targeting APCs and enhancing cancer immunotherapy. Materials Today Bio, 27, 101136.
Kemp, J. A., & Kwon, Y. J. (2021). Cancer nanotechnology for lymphatic imaging and therapy. Nano Convergence, 8(1), 34.
Li, S., Wang, X., Zhang, Y., & Liu, Z. (2026). Targeting cancer-associated neutrophils with biomimetic nano-vaccines loaded with mRNA can enhance the efficacy of immunotherapy for hepatocellular carcinoma. Acta Pharmaceutica Sinica B, 16(5), 1002–1021.
Li, Y., Fang, M., Yu, H., Wang, X., Xue, S., Jiang, Z., Huang, Z., Rong, S., Wei, X., Lu, Z., & Luo, M. (2025). Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines. Biomedicine & Pharmacotherapy, 184, 117897.
Rachamala, H. K., Nakka, N. M. R., Angom, R. S., Wei, F., Nandani, R., Toiemie, Z., Famularo, E. S., Dutta, S. K., Wang, E., Bhattacharya, S., Pal, K., Knutson, K. L., & Mukhopadhyay, D. (2026). Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy. Cancer Letters, 605, 217100.
Uti, D. E., Hameed, S., & Dai, Z. (2026). Imaging-guided delivery/engagement monitoring and theranostic nanovaccine concepts in precision cancer immunotherapy. Cancer Treatment and Research Communications, 47, 101166.
Wang, M., Su, M., Lin, W., Zhang, P., Hou, H., Zeng, F., & Liu, Y. (2026). Spatiotemporal cascade strategy of engineered biomimetic nanovaccines to remodel the solid tumor microenvironment and drive tertiary lymphoid structure neogenesis. Materials Today Advances, 32, 101014.
Wen, Z., Liu, H., Qiao, D., & Qiao, Z. (2023). Nanovaccines fostering tertiary lymphoid structure to attack mimicry nasopharyngeal carcinoma. ACS Nano, 17(8), 7194–7206.
Xiang, J., Xu, L., Gong, H., Zhu, W., Wang, C., Xu, J., Feng, L., Cheng, L., Peng, R., & Liu, Z. (2015). Antigen-loaded upconversion nanoparticles for dendritic cell-targeted tracking and cancer immunotherapy. ACS Nano, 9(6), 6401–6411.
Yang, X., Grippin, A. J., & Mitchell, D. A. (2025). Iron oxide nanoparticle assemblies and magnetic tracking in lymph node delivery and cell trafficking. Molecular Cancer, 24, 225.
Ye, T., Zhang, Y., Wang, X., & Liu, H. (2026). Personalized cancer nanovaccines: Integrating neoantigen biology, engineered delivery platforms, and clinical translation. Signal Transduction and Targeted Therapy, 11, 2769.
Zhao, H., Wang, C., Yi, X., Chao, Y., & Liu, Z. (2019). Nanoscale coordination polymer-based nanovaccine for cancer immunotherapy. ACS Nano, 13(11), 12800–12810.
Zhu, G., Lynn, G. M., Jacobson, O., Chen, K., Liu, Y., Zhang, H., Ma, Y., Zhang, F., Tian, R., Ni, Q., & Chen, X. (2017). Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nature Communications, 8, 1954.
Dissolving Microneedle Patches Match Injected Flu Vaccines While Enabling Self-Administration Without a Cold Chain